WOODCLIFF LAKE, N.J. and SAN DIEGO , July 30, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that an article based on post-hoc analyses from the three pivotal Phase 3 trials of lorcaserin entitled, "Early Weight Loss While on Lorcaserin, Diet, and Exercise as a Predictor of Week 52 Weight-Loss Outcomes," was recently published in the online issue of Obesity , the official peer reviewed journal of The Obesity Society.
- Significantly Improved Agitation in 220-Patient 10-week Study - - Company Plans to Meet with FDA to Discuss Initiation of Pivotal Development Program -
- Data to be Presented at the American Neurological Association Meeting in October - ALISO VIEJO, Calif.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.